Development of improved transient and stable platforms for the scalable clinical manufacture of lentiviral vectors
Engineered viral vectors are effective tools for the development of cell and gene therapies targeting a range of diseases. Current vector manufacturing approaches primarily use fully transient, adherent processes, bringing associated issues of robustness, scalability and high cost-of-goods. To address these issues, we set out to improve the lentiviral (LV) plasmid systems and develop enhanced cGMP compliant, suspension, HEK293 cell lines for both transient and stable manufacture.
Download the resource to continue reading.